KeyBanc analyst Scott Schoenhaus upgraded GoodRx to Overweight from Sector Weight with a $9 price target. The analyst increased estimates and has increased conviction around the company’s monthly active customers, subscriber “green shoots.” The firm also sees tailwinds from “growing eyeballs” in terms of GoodRx’s increased pharma digital advertising opportunities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx files to sell 99.98M shares of Class A common stock for holders
- ‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
- Tesla downgraded, Disney upgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades GoodRx on improved revenue visibility
- GoodRx upgraded to Overweight from Equal Weight at Wells Fargo